Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: The new standard of care

The Lancet Infectious Diseases

Volumn 12, Issue 9, 2012, Pages 717-728

  Pearlman, Brian L ^a,b,c  

^a ATLANTA MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CYTOCHROME P450 3A4; GLYCOPROTEIN P INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RNA POLYMERASE; TELAPREVIR;

AFRICAN AMERICAN; ANEMIA; ANORECTAL DISEASE; ANTIVIRAL THERAPY; BLOOD CELL COUNT; BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DYSGEUSIA; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REVIEW; TABLET; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; STANDARD OF CARE; UNITED STATES;

EID: 84865291164     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70060-9     Document Type: Review

References (80)

1. Kim WR The burden of hepatitis C in the United States. Hepatology 2002, 36(5 suppl 1):S30-S34.
2. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6:35-47. Global surveillance and control of hepatitis C.
3. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
4. Lindenback BD, Rice CM Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
5. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
6. Brenndorfer ED, Brass A, Soderholm J, et al. Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production. Gut 2011, published online Aug 3, 2011. 10.1136/gut.2010.232116.
7. Steinkuhler C, Biasiol G, Brunetti M, et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998, 37:8899-8905.
8. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
9. Bacon BR, Gordon Sc, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
11. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
12. Background material for boceprevir advisory committee division of antiviral products (DAVP) FDA, (accessed Nov 15, 2011). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252341.pdf.
13. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided teleprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365:1014-1024.
14. Foster GR, Zeuzem S, Andreone P, et al. Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorization. J Hepatol 2011, 54(1 suppl):8.
15. Boceprevir FDA, (accessed Nov 15, 2011). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM254079.pdf.
16. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
17. Reau N, Satoskar R, Te H, et al. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol 2011, 106:452-458.
18. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seef LB An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
19. Victrelis package insert (accessed Nov 15, 2011). http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf.
20. Incivek package insert (accessed Nov 15, 2011). http://pi.vrtx.com/files/uspi_telaprevir.pdf.
21. Adda N, Gritz L, Kieffer TL, et al. Futility rules in telaprevir combination treatment. HEP DART; Kauai Hawaii; Dec 4-8. 45.
22. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 363:1292-1303.
23. Berg T, McHutchison JG, Adda F, et al. SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null response, partial response, viral breakthrough or relapse after PR. J Hepatol 2010, 52(1 suppl):4.
24. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011, 140:459-468.
25. VX-950-C211-a dosing regimen study (twice daily versus every 8 hours) of telaprevir in treatment-naive patients with genotype 1 chronic hepatitis C virus infection. July 21, 2011. (accessed Dec 2, 2011). http://clinicaltrials.gov/ct2/show/NCT01241760?term=optimize+hepatitis+c&rank=6.
26. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S Rapid virologic response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011, 55:69-75.
27. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the Study of the Liver.
28. Telaprevir 375-mg film-coated tablet for the treatment of genotype 1 chronic hepatitis C (accessed Dec 2, 2011). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562.pdf.
29. Limaye AR, Draganov PV, Cabrera R Boceprevir for chronic HCV genotype 1 infection. N Engl J Med 2011, 365:176-178.
30. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2-a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124-129.
31. Poordad F, Sulkowski MS, Reddy R, et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimens in the ADVANCE and ILLUMINATE phase 3 studies. Digestive Disease Week; Chicago, Illinois; May 7-10, 2011. 626.
32. Poordad FF, Lawitz EJ, Reddy KR, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; April 18-22, 2012. 1419.
33. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
34. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011, 141:881-889.
35. Imhof I, Simmonds P Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011, 53:1090-1099.
36. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011, 141:1067-1079.
37. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
38. Zhou Y, Bartels D, Hanzelka B, et al. Phenotypic characterization of resistant val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Chemother 2008, 52:110-120.
39. Dieterich DT, Soriano V, Sherman KE, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; March 5-8, 2012 Seattle Washington. 46.
40. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
41. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
42. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
43. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.
44. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. 46th annual meeting of the European Association for the Study of the Liver; Berlin, Germany; March 30-April 3, 2011. 1369.
45. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. 46th annual meeting of the European Association for the Study of the Liver; Berlin, Germany; March 30-April 3, 2011.
46. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. 46th annual meeting of the European Association for the Study of the Liver; Berlin, Germany; March 30-April 3, 2011. 12.
47. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
48. Bartenschlager R, Lohmann V Replication of hepatitis C virus. J Gen Virol 2000, 81:1631-1648.
49. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
50. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve protease inhibitors. Hepatology 2008, 48:1769-1778.
51. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009, 49:1069-1082.
52. Welsch C, Domingues FS, Susser S, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 2008, 9:R16.
53. Fosterier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007, 46:640-648.
54. Reesnink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 2006, 131:997-1002.
55. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008, 49:163-169.
56. Kieffer TL, Sarazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibits wild-type and resistant genotype 1 hepatitis C virus replications in patients. Hepatology 2007, 46:631-639.
57. Pawlotsky JM Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
58. Vierling JM, Kwo PY, Lawitz E, et al. Frequencies of resistance-associated amino acid variants following combination treatment with boceprevir plus pegIntron/ribavirin in patients with chronic hepatitis C, genotype 1. Hepatology 2010, 52:702A.
59. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 2010, 52(4 suppl):227.
60. Volk ML, Tocco R, Saini S, Lok AS Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755.
61. Pearlman BL, Traub N Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011, 52:889-900.
62. Singal AG, Volk ML, Jensen D, DiBisceglie AM, Schoenfeld PS A sustained virologic response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8:280-288.
63. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW Aging of hepatitis c-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
64. Kim WR, Gross JB, Poterucha JJ Comparative effectiveness of antiviral therapy for prior null responders in the era of first generation protease inhibitors. Hepatology 2011, 54(4 suppl):932.
65. Chan J Treatment of chronic hepatitis C: the new standard of care for the future. Formulary 2011, 46:314-336.
66. Ferrante SA, Chhatwal J, Elbasha E, et al. Cost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1. Hepatology 2011, 54(4 suppl):929.
67. Chhatwal J, Ferrante SA, Dasbach EJ, et al. Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin. Hepatology 2011, 54(4 suppl):940.
68. Deniz B, Brogan A, Miller JD, Talbird SE, Thompson JR Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment. Hepatology 2011, 54(4 suppl):943.
69. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD New protease inhibitors for the treatment of chronic hepatitis C. Ann Intern Med 2012, 156:279-290.
70. Phase 3 trial of TMC-435 in treatment-naive, genotype 1 hepatitis C-infected patients (QUEST-1) (accessed Feb 2, 2012). http://clinicaltrials.gov/ct2/show/NCT01289782.
71. Efficacy and safety of BI 201335 in combination with pegylated interferon-alpha and ribavirin in treatment-naive genotype 1 hepatitis C infected patients (accessed Feb 2, 2012). http://clinicaltrials.gov/ct2/show/NCT01343888.
72. Petry As, Fraser IP, O'Mara E, et al. Safety and antiviral activity of MK-5172, a next generation inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 hepatitis C-infected patients. Hepatology 2011, 54(4 suppl):346.
73. Pockros P, Jensen D, Tsai N, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naïve HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol 2011, 54(1 suppl):1359.
74. Pol S, Ghalib RH, Rustgi VK, et al. First report of SVR-12 for a NS5a replication complex inhibitor or BMS-790052 in combination with PEG-IFN a-2a and RBV: phase 2a trial in treatment-naïve HCV-genotype-1 subjects. J Hepatol 2011, 54(1 suppl):1373.
75. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376:1467-1475.
76. Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol 2011, 54:872-878.
77. Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI 201335 and BI 207127, +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2. 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; April 18-22, 2012. 101.
78. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366:216-224.
79. Poordad F, Lawitz E, Kowdley KV, et al. 12-week interferon-free regimen of ABT-450/ritonavir+ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; April 18-22, 2012. 1399.
80. Chayama K, Takashashi S, Kawakami Y, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012, 55:742-748.